Should more infants get protection against severe RSV?

A common winter virus, respiratory syncytial virus (RSV), sends many infants and young children to the hospital with serious breathing problems. Now, a key national health committee has taken a formal step, recommending that doctors use a preventive treatment called nirsevimab for this vulnerable group. Nirsevimab is a long-acting antibody shot, not a traditional vaccine, that helps the body fight off the virus. The recommendation from the Advisory Committee on Immunization Practices is an important guideline for U.S. doctors, but it's just one part of the process. We don't have details from this announcement about how well it worked in studies, what side effects might occur, or how many children were involved. The next practical hurdles are making sure the shot is available and affordable for families who need it.